Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18210863 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL29693578 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL9707240 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL10351784 | 0.93 | PDE4A (0.54) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL21832157 | 0.93 | PDE4A (0.54) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL21832156 | 0.93 | PDE4A (0.54) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL5701179 | 0.93 | PDE4A (0.54) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL5077513 | 0.91 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL10351952 | 0.91 | TDP1 (0.55) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL10351108 | 0.91 | TDP1 (0.55) | LMNAL3MBTL1TDP1PDE4AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7102023-B2 | Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040220389-A1 | Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-04 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0354322-A2 | Antidiabetic alpha-substituted phosphonates | AMERICAN CYANAMID COMPANY (US) | 1990-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220389-A1 | Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries | FUT5, FUT6, UGCG | LMNA 3428/4885L3MBTL1 2678/4885TDP1 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.